Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCCG AT20 multimodality therapy study for atypical teratoid rhabdoid tumor
jRCTs051200071Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiotepa, melphalan and topotecan in Atypical teratoid rhabdoid tumor (ATRT) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
thiotepamelphalantopotecan
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on jRCTs051200071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200071.